Exact Sciences Corp
Exact Sciences Announces Preliminary Q4 2023 Results and CFO Succession Plan
Summary
Exact Sciences Corporation reported preliminary financial results for Q4 and full-year 2023, expecting record Q4 revenue of $645.5-$647.5 million and full-year revenue of $2.50 billion. The company also announced the departure of its CFO, Jeffrey T. Elliott, who will step down in 2024 and serve as a special advisor post-transition. Exact Sciences anticipates 2024 revenue of $2.83 billion.
Profitelligence Alerts
Get alerts for EXAS
Be first to know when Exact Sciences Corp files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Exact Sciences Corp
Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.
Official SEC Documents
Advertisement